Quantcast

Industry news that matters to you.  Learn more

Veristat to Assist on Adaptive Enrichment Trial for Verastem’s Defactinib in Mesothelioma

Reading time: 1 – 2 minutes

Veristat, LLC., a leading, Boston-based clinical research organization, recently announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem, Inc. (NASDAQ: VSTM). The enhanced design aims to optimize the current trial of defactinib, a novel, small molecule inhibitor of focal adhesion kinase (FAK) in patients with malignant pleural mesothelioma.

“We have identified a biomarker in mesothelioma that may predict increased sensitivity to defactinib,” said Dr. Joanna Horobin, Chief Medical Officer at Verastem. “We felt strongly that the application of an enrichment design would help us to accelerate the program to a potential regulatory decision. We are excited to have Veristat’s experience in enrichment trial design and execution supporting this trial.”

Veristat’s input on the overall trial design, as well as the adaptive enrichment design architecture and planned analyses will help facilitate decisions required at key development intersections of the program.

“The Verastem clinical development team has taken a dynamic approach to the design of this study,” commented Dr. John Balser, president and chief science officer at Veristat. “Our team at Veristat will be assisting them with the statistical and operational challenges inherent in the adaptive enrichment design architecture. Our goal is to produce a trial that will quickly and cost effectively yield the highest likelihood of success for their target patient population.”

Source: Veristat